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Activation of various interacting stress kinases, particularly the c-Jun N-terminal kinases (JNK), 
and a concomitant phosphorylation of insulin receptor substrate 1 (IRS-1) at serine 307 play a 
central role both in insulin resistance and in β-cell dysfunction.  IRS-1 phosphorylation is 
stimulated by elevated free fatty acid levels through different pathways in obesity. A series of 
novel pyrido[2,3-d]pyrimidin-7-one derivatives were synthesized as potential antidiabetic 
agents, preventing IRS-1 phosphorylation at serine 307 in a cellular model of lipotoxicity and 
type 2 diabetes. 
 
2015 Elsevier Ltd. All rights reserved. 
 
Keywords: 
Type 2 diabetes 
Lipotoxicity 
c-Jun N-terminal kinase 
IRS-1 phosphorylation 
Pyrido[2,3-d]pyrimidin 
 
  
Type 2 diabetes is a metabolic disorder based on insulin 
resistance and the inability of pancreatic β-cells to adapt by a 
compensatory increase in insulin secretion. 
Activation of various interacting stress kinases, and a 
concomitant phosphorylation of insulin receptor substrate 1 (IRS-
1) at serine 307 play a central role both in insulin resistance and 
in β-cell dysfunction.
1
  Obesity-induced elevation in plasma free 
fatty acid (FFA) levels is deleterious to most cells, and this 
lipotoxicity
2
 is known to enhance IRS-1 serine 307 
phosphorylation, too.
3
  
Multiple interaction with inflammatory signaling, oxidative 
and endoplasmic reticulum (ER) stress as well as accumulation 
of diacylglycerols and ceramide, constitute the major 
mechanisms of FFA-induced serine kinase activation and IRS-1 
serine 307 phosphorylation.
4
  
Insulin acts as an autocrine survival signal in pancreatic β-
cells. Therefore, insulin resistance is pro-apoptotic in these cells, 
and creates a vicious circle by interfering with compensatory 
insulin secretion. Certain stress-activated protein kinases, such as 
c-Jun N-terminal kinases (JNKs) and p38 mitogen-activated 
protein kinase (p38 MAPK) play a prominent role in IRS-1 serine 
phosphorylation. Their inhibition proved to be β-cell protective 
in isolated islets of Langerhans.
5
 Attenuation of IRS-1 Ser307 
phosphorylation as well as reduced JNK phosphorylation and 
activity have been demonstrated to contribute to β-cell protection 
by the widely used insulin sensitizer metformin in ER stress
6
 and 
in lipotoxicity.
7
 Accordingly, JNK inhibitors have been shown to 
protect human β-cells from the deleterious effects of high glucose 
and leptin
8
 and to reduce FFA-induced AP-1 activation and 
apoptosis in INS-1 insulinoma cells.
9
 Moreover, they improved 
functional β-cell mass in transplanted human pancreatic islets 
both in vitro and in vivo in the early post-transplant period.
10
In 
addition, several JNK inhibitors have been shown to improve 
insulin sensitivity and glucose tolerance in db/db diabetic mice
11-
13
 and in mice fed a high-fat diet.
14
  Consequently, JNK inhibitors 
are generally considered as potential antidiabetic agents.
15,16 
JNK as a member of MAPK family also controls cell 
proliferation, survival and DNA repair through phosphorylating a 
wide array of transcription factors (e.g. c-Jun, p53). Therefore, 
specific JNK inhibitors are relevant for multiple medical 
aspects.
17
 However, the molecules that efficiently inhibit IRS-1 
serine 307 phosphorylation are of special importance for anti-
diabetic treatment. The aim of the present study was to apply 
cellular models of lipotoxicity-related and non-related IRS-1 
Ser307 phosphorylation to select inhibitors with the potential to 
prevent or reduce insulin resistance and β-cell dysfunction. 
The compounds tested in this work belong to the NCL of 
Vichem Chemie Research Ltd (Budapest).
18
 We have screened 
Vichem’s EVL library for JNK inhibition. Two compound 
families were identified to be druglike and suitable for 
optimization. The published hit compounds listed in Table 1 were 
used as reference compounds in our experiments. 
Bisphenylamino pyrimidines, the more active JNK inhibitors, 
have nanomolar IC50 values, and the general method of their 
synthesis is well established.
19
 The best known representative of 
this compound family is pazopanib, a multitarget receptor 
tyrosine kinase inhibitor, which acts against renal cell carcinoma 
and soft tissue sarcoma via inhibition of angiogenesis.
16
 Around 
32 000 compounds can be found in SciFinder having 
bisphenylamino pyrimidine core structure, and 610 biological 
activity values were published in 1776 publications, including 
353 review articles. These data show that the chemical space is 
well covered for this core structure. 
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Table 1 Reference compounds synthesized and used in our experiments 
 
The 2,6-disubstituted 7-oxo-pyrido[2,3-d]pyrimidines 
(WO02064594) are p38 MAPK inhibitors of nanomolar IC50 
values with JNK1 inhibitory effect in the micromolar range. The 
most prominent representative of the pyrido[2,3-d]pyrimidin-7-
one core family is palbociclib (Pfizer) (PD-0332991), which is 
known as a selective inhibitor of CDK4 and CDK6 and has been 
recently approved by FDA in combination with letrozole for the 
treatment of postmenopausal women with estrogen receptor 
(ER)-positive, human epidermal growth factor receptor 2 
(HER2)-negative advanced breast cancer.
20
 SciFinder search on 
the pyrido[2,3-d]pyrimidin-7-one core revealed that 9123 such 
derivatives have been published in 681 publications, including 27 
review articles. Based on the literature search, we have found a 
white spot in the chemical space and designed a novel compound 
group containing the pyrido[2,3-d]pyrimidin-7-one core. These 
novel derivatives (listed in Table 2) were synthesized according 
to the scheme shown in Fig 1. Based on Vichem's in-house data 
on JNK pathway inhibitors, 46 analogues were selected for our 
experiments. Instant JChem was used for structure database and 
biological data management.
21
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Figure 1.a: substituted phenol, N-methyl-pirrolidone, K2CO3, 6 h, RT; b: N-
methyl-pirrolidone, K2CO3, 12 h, 120
o
C; c: 3-chloro-perbenzoicacid, CHCl3; 
d: R-amine; e: removing protecting group, salt formation 
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12 
2,4-F2-
Ph 
1-Methane-
sulfonyl-
piperidin-4-
yl 
0.65 2.72 77.17 87.07 
13 
2,4-F2-
Ph 
Piperidin-4-
yl 
10.93 0.00 80.95 118.95 
14 
2,4-F2-
Ph 
Cyclopentyl 5.93 0.00 40.03 66.47 
15 
2,4-F2-
Ph 
4-(4-
Hydroxy-
piperidin-1-
yl)-phenyl 
3.79 0.00 29.64 57.48 
16 
2,4-F2-
Ph 
3-Trifluoro-
methyl-
benzyl 
>23 0.00 94.08 100.89 
17 
2,4-F2-
Ph 
3-(4-Methyl-
piperazin-1-
yl)-propyl 
19.10 0.00 152.84 137.28 
18 
2,4-F2-
Ph 
Cyclohexyl 16.14 0.00 37.58 32.37 
19 
2,4-F2-
Ph 
Cycloheptyl 6.73 0.00 84.01 118.90 
20 
2,4-F2-
Ph 
3-Methane-
sulfonamido
-propyl 
2.77 0.00 52.85 73.54 
21 
2,4-F2-
Ph 
1-Aminos-
ulfonyl-
piperidin-4-
yl 
0.91 0.00 30.50 89.38 
22 
2,4-F2-
Ph 
4-(4-Methyl-
piperazin-1-
yl)-phenyl 
3.34 2.08 133.12 76.93 
23 
2,6-Cl2-
Ph 
Pyridin-2-yl-
methyl 
>23 2.15 35.29 114.89 
24 
2,4-F2-
Ph 
Cyclopropyl 7.17 2.61 173.60 142.31 
25 
2,6-Cl2-
Ph 
Tetrahydro-
pyran-4-yl 
2.48 8.05 55.20 68.02 
26 
2,6-Cl2-
Ph 
Cyclopentyl 19.32 8.18 108.40 114.87 
27 
2,6-Cl2-
Ph 
4-(4-
Hydroxy-
piperidin-1-
yl)-phenyl 
>23 9.09 58.93 74.00 
28 
2,4-F2-
Ph 
2-Methane-
sulfonamido
-ethyl 
18.94 12.21 75.80 67.53 
29 
2,6-Cl2-
Ph 
4-(4-Methyl-
piperazin-1-
yl)-phenyl 
>23 13.20 45.05 60.88 
30 
2,6-Cl2-
Ph 
2-(Pyridine-
2-yl)-ethyl 
>23 14.31 81.60 115.66 
31 
2,6-Cl2-
Ph 
Cyclopropyl 14.92 14.66 96.10 127.74 
32 
2,4-F2-
Ph 
2-
Morpholin-
4-yl-ethyl 
>23 26.71 96.14 102.06 
33 
2,6-Cl2-
Ph 
4-Hydroxy- 
piperidin-1-
yl 
>23 40.48 96.27 99.10 
34 
2,6-Cl2-
Ph 
4-Piperidin-
1-yl-phenyl 
>23 46.31 129.39 107.95 
35 
2,4-F2-
Ph 
3-Hydroxy-
pyrrolodon-
1-yl 
>23 51.06 131.36 111.23 
36 
2,4-F2-
Ph 
Pyridin-2-
methyl 
>23 68.20 68.20 86.15 
37 
2,6-Cl2-
Ph 
2-
Morpholin-
4-yl-ethyl 
27.07 71.26 138.96 114.48 
38 
2,6-Cl2-
Ph 
3-Hydroxy-
pyrrolodin-
1-yl 
>23 74.50 74.50 82.55 
39 
2,4-F2-
Ph 
3-Hydroxy-
methyl-
piperidin-1-
yl 
>23 79.38 21.12 103.36 
40 
2,4-F2-
Ph 
2-Pyridin-2-
yl-ethyl 
6.75 81.98 81.98 96.42 
  
41 
2,4-F2-
Ph 
4-Piperidin-
1-yl-phenyl 
>23 84.01 148.70 130.80 
42 
2,4-F2-
Ph 
3-Hydroxy-
piperidin-1-
yl 
>23 88.71 38.07 103.90 
43 
2,6-Cl2-
Ph 
3-Hydroxy-
piperidin-1-
yl 
>23 93.59 36.24 133.35 
44 
2,4-F2-
Ph 
4-Pyrrolidin-
1-yl-phenyl 
>23 98.90 98.90 107.86 
45 
2,6-Cl2-
Ph 
3-Hydroxy-
methyl-
piperidin-1-
yl 
>23 99.30 99.30 102.90 
46 
2,4-F2-
Ph 
4-Hydroxy-
methyl-
piperidin-1-
yl 
>23 102.35 91.58 120.51 
47 
2,4-F2-
Ph 
2-Dimethyl-
amino-ethyl 
>23 104.31 104.31 110.16 
48 
2,6-Cl2-
Ph 
2-Hydroxy-
methyl-
piperidin-1-
yl 
>23 110.36 110.36 117.82 
49 
2,4-F2-
Ph 
4-Hydroxy-
piperidin-1-
yl 
>23 123.96 121.82 131.10 
50 
2,6-Cl2-
Ph 
4-Hydroxy-
methyl-
piperidin-1-
yl 
>23 127.11 119.26 148.70 
51 
2,6-Cl2-
Ph 
4-Pyrrolidin-
1-yl-phenyl 
>23 165.10 135.70 103.97 
Table 2 The synthesized novel 7-oxo-pyrido[2,3-d]pyrimidines 
Effect of 46 potential inhibitors on JNK activation and JNK-
related protein phosphorylation was tested on HEK293 cells 
treated with the direct (ER-stress-independent) JNK-activator, 
anisomycin. The cellular model was first validated by using BI-
78D3, a known inhibitor of JNK activation. Cells were treated 
with BI-78D3 (various concentrations between 0.1 and 100 µM) 
and anisomycin (50 ng/ml) simultaneously and incubated for 30 
min. Phosphorylated JNK, phosphorylated c-Jun and Ser307-
phosphorylated IRS-1 protein levels were assessed in the cell 
lysates by Western blot. Anisomycin-induced JNK, c-Jun and 
IRS-1Ser307 phosphorylations were counteracted by BI-78D3 in 
a concentration dependent manner (Fig 2). It diminished all these 
three parameters to the limit of detection at 50 µM, and hence it 
was applied at this concentration as a positive control in further 
experiments. The tested molecules were used uniformly at 10 µM 
final concentration among the same experimental conditions.  
 
Figure 2 Inhibition of JNK, c-Jun and IRS-1 Ser 307 phosphorylation in 
anisomycin treated HEK293 cells 
The relative P-JNK, P-c-Jun and Ser307-P-IRS-1 densities 
were quantified by densitometry and compared to those of the 
anisomycin-only-treated samples, which were regarded as 100% 
of activation. As expected, there was a correlation between the 
phosphorylation of JNK and c-Jun proteins, and some tested 
molecules exerted remarkable inhibitory effect on these 
parameters (Table 1 and 2). The observed changes in IRS-1 
Ser307 phosphorylation are less tightly correlated with the extent 
of JNK phosphorylation, in accordance with the multiplicity of 
IRS-1 Ser307 kinases. Further investigation in the present study 
was narrowed down to 12 selected inhibitors (highlighted in the 
tables) based on two inclusion criteria of reducing JNK 
phosphorylation below 65% and also lowering IRS-1 Ser307 
phosphorylation to at least 15% (Table 1 and 2). These 
compounds share 2,6-disubstituted 7-oxo-pyrido[2,3-
d]pyrimidine core structure. 
 
Figure 3 Lipotoxicity-induced JNK phosphorylation in RINm5F insulinoma 
cells 
The 12 kinase inhibitors selected on the basis of their 
effectiveness in anisomycin-treated HEK293 cells were further 
examined in a cellular model of lipotoxicity. A JNK 
phosphorylation level below 61% and an IRS-1 Ser307 
phosphorylation level below 15% in comparison with 
anisomycin-only-treated samples comprised the selection criteria. 
The stress response of RINm5F rat insulinoma cells, including 
JNK, c-Jun and IRS-1 Ser307 phosphorylations, to short term 
saturated fatty acid treatment, has been studied earlier in our 
laboratory.
18
 In this study, the levels of P-JNK and P-IRS-1 were 
assessed in the cells after incubation in the presence of 500 µM 
albumin-conjugated palmitate for 8 hr. JNK phosphorylation was 
inhibited to less than 50% of palmitate only treatment by two of 
the investigated kinase inhibitors, 27 and 18 (54% and 59% 
inhibition, respectively) (Fig 3). These two compounds also 
exerted a remarkable albeit different inhibitory effect on IRS-1 
Ser307 phosphorylation (58% and 93%, respectively) (Fig 4). 
  
 
Figure 4 Lipotoxicity-induced IRS-1 Ser307 phosphorylation in RINm5F 
insulinoma cells 
 
Interestingly, IRS-1 phosphorylation was also markedly 
reduced by another three inhibitors, namely 14 (61%), 20 (87%) 
and 21 (96%) (Fig 4), which in turn did not decrease the level of 
phosphorylated JNK at similar extent (Fig 3). 
Our most effective inhibitors of IRS-1 phosphorylation are 
containing disubstituted phenoxy substituent in position 6 of the 
pyrido-pyrimidine core. 2,4-Difluorophenoxy derivatives showed 
close to 100% inhibition in case of various substituents on 
position 2 amino group e.g. cyclopentylamino, cyclohexylamino, 
methanesulfonamido-propylamino, 1-aminosulfonyl-piperidine-
4-yl substituents gave excellent results. 2,6-Dichlorophenoxy 
substituent in position 6 still resulted <10% IRS-1 
phosphorylation e.g. with tetrahydropyran-4-yl substituent in 
position 2, but several other substituents in position 2 caused 
similar effect also (Table 2). Small scale kinase selectivity of 10 
compounds having IRS-1 Ser307 phosphorylation level below 
15% were determined by Proteros Biostructures at 10 µM or 1 
µM compound concentration (see supplementary material). 
Based on these results the following kinases were hit remarkably: 
Abl, c-kit, DDR1, JNK1, PDGFRβ, Ret, c-Src, VEGFR2. We 
determined IC50 of the reported compounds at 24
h
 on HEK293 as 
a measure of citotoxicity. We found that every compound has 
IC50 over 10 µM and most of them have over 30 µM (see 
supplementary material). 
We aimed to identify and develop new compounds with the 
potential to reduce IRS-1 Ser307 phosphorylation. The selected 
46 compounds were first tested in anisomycin-treated HEK293 
cells and 12 of them were further studied in a cellular model of 
palmitate induced lipotoxicity. Although the signaling 
mechanism that leads to IRS-1 Ser307 phosphorylation in 
palmitate-treated insulinoma cells is more complex, the effects 
observed in this model are much more relevant with respect to 
diabetes pathology and treatment. A remarkable reduction in 
lipotoxicity-induced IRS-1 Ser307 phosphorylation was observed 
in case of 5 compounds, 4 of which also decreased JNK 
phosphorylation at statistically significant, yet smaller extent. It 
seems likely that these molecules act by inhibiting other protein 
kinases involved in IRS-1 phosphorylation beside JNK. 
We have successfully achieved our triple aim: we have started 
a medicinal chemistry optimization starting from druglike JNK 
inhibitor structures in order to obtain novel compounds 
potentially applicable for the treatment of type 2 diabetes. We 
have mapped the structural features taking into account novelty, 
druglikeness, and IRS-1 serine phosphorylation inhibitory 
activity. The development process yielded a narrow group of 
novel structures with excellent inhibitory effect on IRS-1 Ser307 
phosphorylation, opening the opportunity for further drug 
development. 
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